Regenacy Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation for the treatment of diabetic and other peripheral neuropathies and other chronic conditions. The company’s selective inhibition technology provides superior safety profiles and potential enhanced efficacy compared to non-selective HDAC inhibitors. Regenacy selectively inhibits histone deacetylase 6 (HDAC6) to restore normal intracellular protein and organelle transport in peripheral neuropathies, and also has a portfolio of selective HDACs 1 and 2 inhibitors that have potential to treat major blood diseases such as leukemia, sickle cell disease, β-thalassemia, and cognitive dysfunction in neurological disorders.

Biotechnology

Regenacy Pharmaceuticals

Simon S. Jones

Matthew Jarpe

Timothy Kachmar

The Regulatory and Advisory Team at Regenacy Pharmaceuticals is responsible for ensuring compliance with regulatory standards throughout the drug development process. This team collaborates with external advisory board members to provide strategic scientific guidance, facilitating the advancement of innovative therapies for chronic conditions. They also engage with regulatory agencies to navigate approval pathways effectively, ensuring that products meet safety and efficacy requirements before reaching the market.

Regulatory and Advisory Team

About

Team members

Other teams at Regenacy Pharmaceuticals

Leadership Team